Research programme: CNS peptide therapeutics - BioMarin Pharmaceutical
Alternative Names: CNS Peptide- BioMarin PharmaceuticalLatest Information Update: 01 Dec 2023
At a glance
- Originator BioMarin Pharmaceutical
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 22 Sep 2023 Discontinued for CNS disorders in USA (Parenteral) (BioMarin Pharmaceuticals pipeline, September 2023)